Twelve addiction treatment centers and Aetna Behavioral Health collaborate using the Advancing Recovery systems change model to increase the proportion of patients with medication-assisted treatment for alcohol or opioid dependence. The addiction treatment centers participate in a 22-month test of the system change strategy to enhance access to medication for patients dependent on opioids or alcohol. The proposal has three specific aims: 1) facilitate adoption of medications, 2) assess impacts on healthcare utilization and expenditures, and 3) conduct qualitative interviews and document implementation barriers and change strategies. Analyses of Aetna's databases track use of health and behavioral health services to assess medication impacts on the utilization and cost of care.
Specific Aim 1 : Use the Advancing Recovery model of system change to accelerate the implementation of medication-assisted treatment and integration with medical care;assign 12 addiction treatment centers to Advancing Recovery and compare to 12 matched comparison sites. 7 H1A: The proportion of opioid and alcohol admissions with prescriptions for addiction medications is greater in centers using the Advancing Recovery system change model. 7 H1B: Advancing Recovery sites form linkages with more prescribers and have more physicians writing prescriptions for patients.
Specific Aim 2 : Assess impacts on the utilization of and expenditures for inpatient, emergency and residential care using Aetna's utilization and expenditures data. 7 H2A: Utilization of and expenditures for inpatient medical care, emergency services, and residential addiction treatment will be lower among patients treated in sites participating in Advancing Recovery. 7 H2B: Utilization of and expenditures for inpatient medical care, emergency services, and residential addiction treatment will be lower among patients treated with addiction medications. 7 H2C: Utilization of and expenditures for inpatient medical care, emergency services, and residential addiction treatment will be lower among patients with more consecutive months of medication prescriptions.
Specific Aim 3 : Conduct qualitative interviews to document implementation barriers and effective implementation strategies for medication assisted treatment. 7 H3A: Provider training and attitudes are more problematic barriers to adoption than payment and reimbursement issues. 7 H3B: Centers with no experience with buprenorphine will be more likely to use extended release naltrexone for treatment of opioid dependence.
More than 18 million US residents meet criteria for alcohol dependence or abuse and 2 million are dependent on non-medical use of prescription opioids (Substance Abuse and Mental Health Services Administration, 2010);rates of current use, moreover, appear to be increasing (Compton &Volkow, 2006) and are associated with more overdose fatalities (Hall et al., 2008) and visits to emergency departments (Novak &Ball, 2006). Patients and practitioners seek better treatments but counselor and patient reluctance to use medication-assisted treatments and weak linkages with medical care lead to an underutilization of pharmacotherapy. The Medications Research Partnership uses the Advancing Recovery implementation model to make system changes and support increased access to medication-assisted therapy for patients covered by a commercial health plan.
|Ford 2nd, James H; Abraham, Amanda J; Lupulescu-Mann, Nicoleta et al. (2017) Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System Change. J Stud Alcohol Drugs 78:735-744|
|McCarty, Dennis; Rieckmann, Traci; Baker, Robin L et al. (2017) The Perceived Impact of 42 CFR Part 2 on Coordination and Integration of Care: A Qualitative Analysis. Psychiatr Serv 68:245-249|
|Schmidt, Laura A (2016) Recent Developments in Alcohol Services Research on Access to Care. Alcohol Res 38:27-33|
|Yarborough, Bobbi Jo H; Stumbo, Scott P; McCarty, Dennis et al. (2016) Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol Depend 160:112-8|
|Alanis-Hirsch, Kelly; Croff, Raina; Ford 2nd, James H et al. (2016) Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. J Subst Abuse Treat 62:68-73|
|Kim, Hyunjee; Hartung, Daniel M; Jacob, Reside L et al. (2016) The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program. Psychiatr Serv 67:397-404|
|McCarty, Dennis; Bovett, Rob; Burns, Thomas et al. (2015) Oregon's strategy to confront prescription opioid misuse: a case study. J Subst Abuse Treat 48:91-5|
|Rieckmann, Traci; Abraham, Amanda; Zwick, Janet et al. (2015) A Longitudinal Study of State Strategies and Policies to Accelerate Evidence-Based Practices in the Context of Systems Transformation. Health Serv Res 50:1125-45|
|Hartung, Daniel M; McCarty, Dennis; Fu, Rongwei et al. (2014) Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat 47:113-21|
|Green, Carla A; McCarty, Dennis; Mertens, Jennifer et al. (2014) A qualitative study of the adoption of buprenorphine for opioid addiction treatment. J Subst Abuse Treat 46:390-401|
Showing the most recent 10 out of 14 publications